Flash Finance

Bal Pharma LimitedBALPHARMACorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹95.75
MCap ₹152 Cr · P/E 20.1
Bal Pharma Limited — Stock analysis & AI research Bal Pharma Limited — Multibagger AI analysis Bal Pharma Limited — Seasonality — best & worst months Bal Pharma Limited — Technical setup — score, trend, support & resistance Bal Pharma Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹88 Cr
Sales · Jun 2026
+34.7% YoY
₹8 Cr
Operating Profit · Jun 2026
+29.2% YoY
9.0%
OPM % · Jun 2026
-4.3% YoY
₹1 Cr
Net Profit · Jun 2026
+259.3% YoY
₹0.73
EPS · Jun 2026
+265.0% YoY

📝 Bal Pharma Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Bal Pharma Limited reported revenue of ₹88 crore for the quarter ended June 2026 (Q1 FY27), up 34.7% from ₹66 crore in the same quarter last year, and up 5.4% sequentially over the March 2026 quarter.

Net profit rose 259.3% year-on-year to ₹1 crore, from ₹0 crore. Earnings per share (EPS) came in at ₹0.73.

Operating profit stood at ₹8 crore — an operating margin (OPM) of 9.0%, compared with 9.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Bal Pharma Limited posted revenue of ₹311 crore, a growth of 2.7% over FY25, with a net profit of ₹7 crore (down 30.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹334 crore with a net profit of ₹8 crore.

Valuation snapshot

At the current price of ₹95.75, BALPHARMA has a market capitalisation of ₹152 crore and a trailing P/E of about 20.1.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 50.86%, foreign institutional investors (FIIs) 0.28%, public shareholders 48.87% of Bal Pharma Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹152 Cr
Current Price ?
₹95.8
P/E ?
20.09below ind
Industry P/E ?
37.20
P/B ?
1.47
P/S ?
0.46
P/FCF ?
19.06
Enterprise Value ?
₹306 Cr
EV/EBITDA ?
9.00
PEG ?
6.70
Earnings Yield ?
7.4%
Dividend Yield ?
1.26%
Profitability & Returns
Sales (TTM) ?
₹334 Cr
OPM ?
10.2%
Profit after tax (TTM) ?
₹8 Cr
EPS (TTM) ?
₹4.77
ROCE ?
9.0%
ROE ?
7.3%
ROA ?
1.9%
Growth
Sales — latest qtr ?
₹88 Cr
PAT — latest qtr ?
₹1 Cr
YoY qtr sales growth ?
34.7%
YoY qtr profit growth ?
259.3%
Sales growth (3y) ?
1%
Sales growth (5y) ?
5%
Profit growth (3y) ?
3%
Profit growth (5y) ?
-6%
Financial Health
Debt ?
₹154 Cr
Debt to Equity ?
1.48
Interest Coverage ?
1.3
Current Ratio ?
N/A
Ownership
Promoter holding ?
50.86%
Change in promoter holding ?
-0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
10.1%
Return 6 months ?
22.4%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 778270928195737573826674878488 +34.7% +5.4%
Operating Profit 687881077886610118 +29.2% -25.2%
Other Income 1000021011110-00 -38.3% +307.8%
Interest 344444446444544 +10.2% +10.3%
Depreciation 222232222232333 +10.4% -8.5%
Profit Before Tax 232227221301231 +259.3% -65.0%
Net Profit 121216211601241 +259.3% -68.6%
EPS 0.941.350.761.020.804.161.110.760.733.510.200.491.222.320.73 +265.0% -68.5%
OPM % 8.2% 10.1% 9.8% 8.3% 9.4% 10.9% 9.7% 10.0% 11.4% 9.6% 9.4% 7.8% 11.1% 12.7% 9.0% -4.3% -29.1%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹302 Cr ₹311 Cr ₹334 Cr +2.7%
Operating Profit ₹31 Cr ₹32 Cr ₹34 Cr +5.0%
OPM % 10.15% 10.37% 10.20% +2.2%
NPM % 3.21% 2.17% 2.27% -32.4%
Other Income ₹3 Cr ₹2 Cr ₹2 Cr -32.6%
Depreciation ₹9 Cr ₹11 Cr ₹11 Cr +28.7%
Interest ₹17 Cr ₹17 Cr ₹17 Cr -3.6%
EBIT ₹22 Cr ₹21 Cr ₹23 Cr -4.3%
PBT ₹8 Cr ₹6 Cr ₹7 Cr -16.7%
Tax ₹-2 Cr — — —
Net Profit ₹10 Cr ₹7 Cr ₹8 Cr -30.5%
EPS ₹6.11 ₹4.23 ₹4.76 -30.8%
Material Cost ₹165 Cr ₹128 Cr ₹139 Cr -22.7%
Employee Cost ₹59 Cr ₹48 Cr ₹50 Cr -18.5%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 16161616 +0.0%
Reserves 80778388 +6.0%
Borrowings 125134145154 +6.2%
Other Liabilities 126108107133 +24.3%
Total Liabilities 348334351391 +11.4%
Fixed Assets 63798794 +8.0%
CWIP 0037 +133.3%
Investments 8954 -20.0%
Other Assets 276245256285 +11.3%
Total Assets 348334351391 +11.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 5292030 +50.0%
Cash from Investing Activity -22-19-15-21 -40.0%
Cash from Financing Activity 17-7-8-10 -25.0%
Net Cash Flow 03-20 +100.0%
Free Cash Flow -91828 +300.0%
CFO/OP 22%104%74%94% +27.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 114110114113 -0.9%
Inventory Days 210167238269 +13.0%
Days Payable 195148189206 +9.0%
Cash Conversion Cycle 129129163176 +8.0%
Working Capital Days 61322930 +3.4%
ROCE % 10%11%10%9% -10.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 50.87%50.87%50.87%50.87%50.86% -0.0%
FIIs 0.15%0.23%0.14%0.14%0.28% +100.0%
Public 48.99%48.91%49.01%49.01%48.87% -0.3%
No. of Shareholders 15,82615,77415,52015,21415,241 +0.2%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 BALPHARMA Bal Pharma ₹110.89 177 24.5 334 7 10.1% 2.2% 2.9% -19.8% 34.5% 445.7%
❓ Frequently asked questions
What was Bal Pharma Limited's revenue in Q1 FY27?
Bal Pharma Limited reported revenue of ₹88 crore for the quarter ended June 2026 (Q1 FY27), up 34.7% from ₹66 crore in the same quarter last year, and up 5.4% sequentially over the March 2026 quarter.
What was Bal Pharma Limited's net profit in Q1 FY27?
Net profit rose 259.3% year-on-year to ₹1 crore, from ₹0 crore. Earnings per share (EPS) came in at ₹0.73.
What is BALPHARMA's market capitalisation and P/E ratio?
At the current price of ₹95.75, BALPHARMA has a market capitalisation of ₹152 crore and a trailing P/E of about 20.1.
Who owns Bal Pharma Limited? (shareholding pattern)
As of Sep 2026, promoters held 50.86%, foreign institutional investors (FIIs) 0.28%, public shareholders 48.87% of Bal Pharma Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI